Efficacy of Taletrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC By Ogkologos - April 18, 2025 596 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an integrated analysis of the pivotal phase II regional TRUST-I and global TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Will politics keep us from accessing EU science funding? July 25, 2022 ESMO Immuno-Oncology Congress 2023, 6-8 December 2023, Geneva, Switzerland November 29, 2023 A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and... August 11, 2025 Patient Exposure to Anticancer Drugs Subsequently Withdrawn from the FDA Accelerated... March 9, 2023 Load more HOT NEWS FDA Approval of KRAS Inhibitor Sotorasib for Lung Cancer Hailed as... Foodie Friday: Couscous Salad Immunotherapy Plus Chemotherapy Helps People With Advanced Nasopharyngeal Cancer: The ASCO... New on NCI Websites for December 2018
